This article is more than 5 years old. Information may no longer be current.
NeuroStar launches registry to assess TMS for depression
NeuroStar recently announced the launch of a large depression outcomes registry for individuals treated with its transcranial magnetic stimulation therapy.
“There are currently more than 740 NeuroStar providers across the U.S., with over one million treatments delivered to-date,” Mark Demitrack, MD, chief medical officer of NeuroStar, said in a press release. “We are thrilled to roll out this registry to participating physicians and are striving for it to become the largest depression patient database ever. The primary objective of the multisite, observational dataset is to report disease state outcomes for MDD patients treated with NeuroStar Advanced Therapy using validated clinical rating scales, thus enabling better patient care through easy, efficient outcomes analysis.”
The registry is intended to determine the clinical utility of NeuroStar TMS. The company expects to collect data for more than 6,000 individuals with depression across at least 100 treatment facilities in the U.S.
“In the long term, the research obtained from this registry has the potential to change the way we provide care to people with chronic depression,” Kenneth P. Pages, MD, medical director of TMS of South Tampa, said in the release. “The information collected over the years will equip physicians with case histories and the necessary research to tailor the most effective treatment plans. This, in turn, will allow us to better understand and ultimately meet the needs of these patients.”